ReviewJournal of thrombosis and thrombolysis2003
A review of the clinical uses of ximelagatran in thrombosis syndromes.
Review in Journal of thrombosis and thrombolysis, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 9 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ximelagatran, an oral direct thrombin inhibitor, has been investigated for the prevention and treatment of venous thromboembolism as well as for anticoagulation in atrial fibrillation. Unique properties of ximelagatran are that it is a prodrug, it does not require routine laboratory monitoring and it has minimal drug interactions. The dose of ximelagatran needs to be modified in patients with renal failure; however, dosing guidelines in this specific patient population have not been established. Preliminary and emerging data suggest that ximelagatran is superior or at least as effective as low molecular weight heparins and warfarin in the setting of venous thromboembolism prevention and treatment. Ximelagatran has comparable bleeding rates to low molecular weight heparins and warfarin; however, it is associated with transient elevations in hepatic transaminases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.